ITP
RVNC

Iron Triangle Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

Iron Triangle Partners’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-330,000
Closed -$9.19M – 32
2021
Q3 		$9.19M Buy
+330,000
New +$9.42M 1.32% 24

Other funds holding RVNC

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Iron Triangle Partners's RVNC Position: Q4 2021 in Review

Iron Triangle Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2021, closing a stake of 330,000 shares — an estimated $9.19M sold.

Iron Triangle Partners first reported a position in RVNC in Q3 2021 and held it in 1 quarter. The position peaked at $9.19M in Q3 2021. 151 funds tracked by Wall St. Rank hold RVNC as of Q4 2021.

  • Iron Triangle Partners reported no remaining Revance Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
  • Iron Triangle Partners sold 330,000 Revance Therapeutics, Inc. shares in Q4 2021, an estimated $9.19M.
  • Iron Triangle Partners first reported a position in Revance Therapeutics, Inc. in Q3 2021 and held it in 1 quarter.
  • Iron Triangle Partners's Revance Therapeutics, Inc. position peaked at $9.19M in Q3 2021.
  • 151 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2021.

Based on Iron Triangle Partners's 13F filing for Q4 2021, filed 14 Feb 2022.